Clonal dominance of CD133+ subset population as risk factor in tumor progression and disease recurrence of human cutaneous melanoma

International Journal of Oncology

Volumn 41, Issue 5, 2012, Pages 1570-1576

  Sharma, Bhuvnesh K ^a,d   Manglik, V ^c   O'Connell, Michael ^e   Weeraratna, Ashani ^e   McCarron, Edward C ^a   Broussard, Jennifer N ^b   DiVito, Kyle A ^d   Simbulan Rosenthal, Cynthia M ^d   Rosenthal, Dean S ^d   Zapas, John L ^a  

^a Harry and Jeanette Weinberg Cancer Institute   (United States)

^b MedStar Franklin Square Medical Center ^*  (United States)

^c ELIZABETH CITY STATE UNIVERSITY   (United States)

^d GEORGETOWN UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e WISTAR INSTITUTE   (United States)

Author keywords

CD133; Disease recurrence; Human melanoma

Indexed keywords

CD133 ANTIGEN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER RISK; CONTROLLED STUDY; CUTANEOUS MELANOMA; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MELANOMA CELL; METASTASIS; MONITORING; MOUSE; NONHUMAN; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHENOTYPE; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; RECURRENT DISEASE; TUMOR GROWTH; UPREGULATION;

ANIMALS; ANTIGENS, CD; CELL LINE, TUMOR; CELL TRANSFORMATION, NEOPLASTIC; DISEASE PROGRESSION; GLYCOPROTEINS; HUMANS; MELANOMA; MICE; MICE, NUDE; NEOPLASM METASTASIS; NEOPLASTIC STEM CELLS; PEPTIDES; RECURRENCE; RISK FACTORS; SKIN NEOPLASMS; TRANSPLANTATION, HETEROLOGOUS; TUMOR MARKERS, BIOLOGICAL;

EID: 84867756302     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2012.1590     Document Type: Article

References (26)

1. Reya T, Morrison SJ, Clarke MF and Weissman IL: Stem cells, cancers, and cancer stem cells. Nature 414: 105-111, 2001.
2. Al-Haj IM, Wicha MS, Benito-Hernandez A, Morrison SJ and Clarke MF: Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA 100: 3983-3988, 2003. (Pubitemid 36418143)
3. Singh SK, Clarke ID, Terasaki M, Bonn VE, Hawkins C, Squire J and Dirks DB: Identification of a cancer stem cell in human brain tumors. Cancer Res 63: 5821-5828, 2003. (Pubitemid 37187480)
4. Wulf GG, Wang RY, Kuehne I, Weinder D, Marini F, Brenner MK, Andreeff M and Goodell MA: A leukemic stem cell with intrinsic drug efflux capacity in acute myeloid leukemia. Blood 98: 1166-1173, 2001.
5. Kondo T, Setoguch T and Taga T: Persistence of a small subpopulation of cancer stem like cells in the C6 glioma cell line. Proc Natl Acad Sci USA 101: 781-786, 2004. (Pubitemid 38121035)
6. Grichnik JM, Burch JA, Schulteis RD, Shan S, Liu J, Darrow TL, Vervaert CE and Seigler HF: Melanoma, a tumor based on a mutant stem cell? J Invest Dermatol 126: 142-153, 2006. (Pubitemid 43336106)
7. Fang D, Nguyen TK, Leishear K, Finko R, Kulp AN, Hotz S, van Belle PA, Xu X, Elder DE and Herlyn M: A tumorigenic subpopulation with stem cell properties in melanomas. Cancer Res 65: 9328-9337, 2005. (Pubitemid 41508000)
8. Zabierowski SE and Herlyn M: Melanoma stem cells: the dark seed of melanoma. J Clin Oncol 26: 2890-2894, 2008.
9. Klein WM, Wu BP, Zhao S, Wu H, Klein-Szanto AJP and Tahan SR: Increased expression of stem cell markers in malignant melanoma. Mod Pathol 20: 102-107, 2007. (Pubitemid 44967955)
10. Sharma BK, Manglik V and Elias EG: Immunoexpression of melanoma stem cell markers in various stages of disease in human melanoma. J Surg Res 163: e11-e15, 2010.
11. Park CY, Tseng D and Weisman IL: Cancer stem cells-directed therapies: recent data from laboratory and clinic. Mol Ther 172: 219-230, 2009.
12. Weissman I: Stem cell research: paths to cancer therapies and regenerative medicine. JAMA 294: 1359-1366, 2005.
13. Shmelkov SV, St Chair R, Lyden D, et al: AC133/CD133/Prominin-1. Int J Biochem Cell Biol 37: 715-719, 2005. (Pubitemid 40202993)
14. Schatton T, Murphy GF, Frank NY, Yamaura K, Wagga-Gasser AM, Gasser M, Zhan Q, Jordan S, Duncan LM, Weishaupt C, Fuhlbrigge RC, Kupper TS, Sayegh MH and Frank MH: Identification of cells initiating human melanomas. Nature 451: 345-349, 2008.
15. Swart GW, Lunter PC, Kilsdonk JW, et al: Activated leukocyte cell adhesion molecule (ALCAM/CD166): signaling at the divide of melanoma cell clustering and cell migration? Cancer Metastasis Rev 24: 223-236, 2005. (Pubitemid 40922796)
16. Florenes VA, Holm R, Myklebost O, et al: Expression of the neuro-ectodermal intermediate filament Nestin in human melanomas. Cancer Res 54: 354-356, 1994. (Pubitemid 24053166)
17. Tomayko MM and Reynolds CP: Determination of subcutaneous tumor size in athymic (nude) mice. Cancer Chemother Pharmacol 24: 148-154, 1989. (Pubitemid 19163397)
18. Euhus DM, Hudd C, La Regina MC and Johnson FE: Tumor measurement in the nude mouse. J Surg Oncol 31: 229-234, 1986. (Pubitemid 16104025)
19. Botchkina IL, Rowehl RA, Rivadenneira DE, Karpeh MS Jr, Crawford H, Dufour A, Ju J, Wang Y, Leyfman Y and Botchkina GI: Phenotypic subpopulations of metastatic colon cancer stem cells: genomic analysis. Cancer Genomics Proteomics 6: 19-29, 2009.
20. Tirino V, Camerlingo R, Franco R, Malanga D, La Rocca A, Viglietto G, Rocco G and Pirozzi G: The role of CD133 in the identification and characterization of tumor-initiating cells in non-small cell lung cancer. Eur J Cardiothorac Surg 36: 446-453, 2009.
21. + cells display stem-like features and are spared by cisplatin treatment. Proc Natl Acad Sci USA 106: 16281-16286, 2009.
22. Bao S, Wu Q, McLendon RE, Hao Y, Shi Y, Hjelmeland AB, Dewhirst MW, Bigner DD and Rich JN: Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 444: 756-760, 2006. (Pubitemid 44949604)
23. Chiou SH, Yu CC, Huang CY, Lin SC, Liu CJ, Tsai TH, Chou SH, Chien CS, Ku HH and Lo JF: Positive correlations of Oct-4 and Nanog in oral cancer stem-like cells and high-grade oral squamous cell carcinoma. Clin Cancer Res 14: 4085-4095, 2008.
24. Clarke MF, Dick JE, Dirks PB, Eaves CJ, Jamieson CH, Jones DL, Visvader J, Weismann IL and Wahl GM: Cancer stem cells-perspectives on current status and future directions: AACR Workshop on cancer stem cells. Cancer Res 66: 9339-9344, 2006.
25. Monzani E, Facchetti F, Galmozzi E, Corsini E, Benetti A, Cavazzin C, Gritti A, Piccinini A, Porro D, Santinami M, Invernici G, Parati E, Alessandari G and La Porta CA: Melanoma contains CD133 and ABCG2 positive cells with enhanced tumourigenic potential. Eur J Cancer 43: 935-946, 2007. (Pubitemid 46366698)
26. Rappa G, Fodstad O and Lorico A: The stem cell-associated antigen CD133 (Prominin-1) is a molecular therapeutic target for metastatic melanoma. Stem Cells 26: 3008-3017, 2008.